Skip to main content
. Author manuscript; available in PMC: 2010 Jul 1.
Published in final edited form as: Clin Endocrinol (Oxf). 2008 Dec 5;71(1):11–17. doi: 10.1111/j.1365-2265.2008.03496.x

Table 1.

Number of scans performed

Nr. of patients CT MRI CT and/or MRI [18F]-FDA [123I]-MIBG [131I]-MIBG [123I] or [131I]-MIBG
Non-metastatic
PHEO 26 26 (100%) 20 (77%) 26 (100%) 26 (100%) 21 (81%) 2 (8%) 23 (88%)
Metastatic PHEO 34 32 (94%) 31 (91%) 34 (100%) 34 (100%) 21 (62%) 10 (29%) 31 (91%)
PHEO total 60 58 (97%) 51 (85%) 60 (100%) 60 (100%) 42 (70%) 12 (20%) 54 (90%)
No PHEO 39 29 (74%) 25 (64%) 31 (79%) 39 (100%) 21 (54%) 2 (5%) 23 (59%)
Total 99 87 (88%) 76 (77%) 91 (92%) 99 (100%) 63 (64%) 14 (14%) 77 (78%)